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ABSTRACT (100 Word Limit) 2 
We conducted a genome-wide association study for blood pressure (BP) in 776,078 participants 3 
from the Million Veteran Program (MVP) and collaborating studies and discovered 207 novel 4 
loci from common-variant analyses and 54 rare variants. In a follow-up transcriptome-wide 5 
association study, we identified 3,036 associations between BP traits and genetically-predicted 6 
gene expression of 834 genes across 45 tissues. We identified pleiotropic effects from a 7 
phenome-wide association study and potential therapeutic targets from gene-drug relationships 8 
and toxicities. We also report structures from proximal tubule to collecting ducts that 9 
overexpress several BP gene homologs, using data from single-cell RNA sequencing in mice. 10 
11 
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Decades of scientific evidence implicate elevated blood pressure (BP) in the etiology of 12 
cardiovascular disease, including coronary artery disease, peripheral arterial disease, and stroke, 13 
as well as renal, and ocular damage. Elevated BP accounts for at least 13% of annual deaths 14 
worldwide1,2. The risk of death from ischemic heart disease and stroke increases linearly for 15 
systolic blood pressure (SBP) greater than 115 mmHg and diastolic blood pressure (DBP) greater 16 
than 75 mmHg3. Recent treatment guidelines emphasize the benefit of BP-lowering strategies, 17 
including drug treatments, at lower thresholds of SBP or DBP4. These guidelines also identify a 18 
substantial patient population who are untreated or undertreated for elevated BP, or do not have 19 
the appropriate treatment response to anti-hypertensive drugs, highlighting the need to identify 20 
new gene targets for therapies5. 21 
Large-scale genome-wide association studies (GWAS) have collectively reported over 22 
250 loci associated with BP traits4-19, establishing that BP traits are complex with many genetic 23 
determinants of modest effects6–24. Large population studies of BP with collaborating cohorts 24 
and embedded meta-analyses provide an opportunity to identify genetic loci that are 25 
determinants of SBP, DBP and pulse pressure (PP) levels. In this trans-ethnic study, we meta-26 
analyzed data for 318,891 Million Veteran Program (MVP) participants and 140,886 participants 27 
from the UK Biobank (UKB)12. We subsequently performed independent replication in 316,301 28 
participants from the International Consortium for Blood Pressure (ICBP) and Vanderbilt 29 
University’s BioVU cohort to study common variant associations with minor allele frequency 30 
(MAF) greater than 1% (Figure 1). We conducted two studies of rare variants, one focused on 31 
variants across the genome with independent replication in 458,577 participants from UKB and 32 
the other focused on exomic regions with replication in up to 417,143 participants from the 33 
Blood Pressure-International Consortium of Exome chip studies (BP-ICE) consortium. We 34 
extend findings in the literature by evaluating genetically predicted gene expression (GPGE) and 35 
related gene-drug relationships and toxicities, by conducting a phenome-wide association study 36 
(PheWAS) of BP genetic risk scores, and by performing functional studies to identify murine 37 
kidney cell types in which expression for implicated genes is enriched.  38 
 39 
RESULTS 40 
MVP participants (N = 318,891), representing the majority of the discovery sample size, were 41 
predominantly male (91.5%), and were administratively identified as whites (69.1%), with 42 
blacks and Hispanics representing 18.8% and 6.7% of the population respectively 43 
(Supplementary Table 1). Blacks were older on average [mean = 60.6 years, (standard deviation 44 
= 11.4)], followed by whites [58.9 (12.6)], and Hispanics [52.7 (14.5)]. Approximately half of 45 
the MVP participants were on antihypertensive medications and a quarter had diabetes. 46 
Participants from the UKB (N = 140,886) were also included in the discovery analysis; their 47 
characteristics are reported elsewhere12.  48 
Single Variant Analyses 49 
Common Variants 50 
We identified a total of 505 independent loci (207 novel loci, 298 previously reported) associated 51 
with one or more BP traits: SBP, DBP and PP. Among the previously reported loci 212 were 52 
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associated with SBP, 76 with DBP and 205 with PP (Table 1; Fig. 2a-c; Supplementary Tables 53 
2a-c). Previously reported loci were not evaluated for further replication. Remaining loci were 54 
sought for replication with the ICBP consortium though meta-analysis to identify 207 novel loci. 55 
These included 128 loci for SBP, 4 loci for DBP and 126 loci for PP (Supplementary Tables 3a-56 
c). Comparison of mean effect estimates of BP-trait increasing alleles showed that, on average, 57 
novel loci had smaller magnitudes of association than known loci (Table 1). The index SNPs at 58 
all independent loci from analysis of common variants explained 3.56%, 1.06% and 3.72% of the 59 
total variance for SBP, DBP and PP respectively. Novel variants contributed to 0.80%, 0.24% 60 
and 0.72% of the total variance explained by all independent loci for SBP, DBP, and PP, 61 
respectively.  62 
Exonic Variants 63 
Rare exonic variants with suggestive evidence of association (P-value = 5x10-6) from the 64 
discovery sample were queried for replication in populations from BioVU (N = 17,277) and the 65 
BP-ICE (Nmax = 417,143) consortium. Eighteen variants were available for final meta-analysis. 66 
Ten missense variants from seven genes were associated with BP traits (Table 2). Five variants 67 
were associated with SBP and/or DBP (rs141328069 [PDE3A; ArgGln], rs139491786, 68 
[SLC9A3R2; ArgTrp], rs61760904 [RRAS; AspAsn], rs73181210 [PHC3; LysGlu], 69 
rs3085380 [DBH; Gly  Ala]) with consistent directions of effect for SBP and DBP. Three rare 70 
variants from COL21A1 (rs118079907 [CysArg], rs200999181 [GlyVal], and rs2764043 71 
[LeuPro]) and one variant from NOX4 (rs139341533; LeuPhe) were significantly associated 72 
with PP but not with SBP or DBP and in fact had opposite directions effect for SBP and DBP. 73 
SNPs in RRAS, DBH, and one of the three SNPs in COL21A1 (rs200999181) have been 74 
previously reported22–24. Average absolute values of effect estimates for SBP, DBP and PP in 75 
these variants were 1.52, 0.63, and 1.50 mmHg per allele, respectively.  76 
Rare Variants 77 
Discovery analysis in the MVP samples identified 1,684 rare variants with suggestive evidence 78 
for association across the three BP traits; 1,066 of these variants were available for meta-analysis 79 
from UKB. We observed statistically significant associations (P-value = 5x10-8) between 48 rare 80 
variants and one or more BP traits. We identified 40 SNPs for PP, eight SNPs for SBP, and two 81 
SNPs for DBP (Supplementary Table 4). Average absolute values of effect estimates for SBP, 82 
DBP and PP were 9.67, 2.33 and 13.89 mmHg per allele, respectively. The missense variants 83 
from NOX4 (rs139341533), SLC9A3R2 (rs139491786), and COL21A1 (rs200999181, 84 
rs2764043) were evaluated in the both the exonic and rare-variant analyses separately (Table 2; 85 
Supplementary Table 4).  86 
Transcriptome-Wide Association Analyses 87 
Genetically-Predicted Gene Expression (GPGE) in Human Tissues 88 
Common variants from the  final meta-analysis were used to evaluate the associations between 89 
BP traits and GPGE levels across 44 Gene Tissue Expression Project (GTEx)25 tissues using S-90 
PrediXcan26. We identified statistically significant GPGE associations for 1,518 gene-tissue pairs 91 
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with SBP, 507 with DBP, and 1,938 for PP (Supplementary Tables 5a-c; Supplementary Figures 92 
1a-c). We further identified 390 genes with this analysis that would not be identified if SNPs 93 
were annotated using the nearest gene. The proportion of significant associations that occurred in 94 
five cardiovascular tissues (aorta, coronary artery, tibial artery, left ventricle, and atrial 95 
appendage) were 16.7% for PP (P-value = 1.5x10-6), 15.9% for SBP (P-value = 3.0x10-4), and 96 
15.6% (P-value = 5.4x10-2) for DBP, an enrichment over the expected 11.4% if all tissues were 97 
represented equally. MTHFR was the top result from SBP and showed decreasing SBP with 98 
increasing GPGE in skeletal muscle, aorta, and several other tissues.  99 
Colocalization of eQTLs and BP SNPs in Human Kidney 100 
The GTEx reference data do not include sufficient numbers of kidney specimens to derive 101 
predictive weights for S-PrediXcan analysis. We applied the R package COLOC27 to the kidney 102 
expression quantitative trait locus (eQTL) reference described by Ko et al28 and our BP GWAS 103 
summary statistics to identify gene-SNP pairs with evidence for causal association for both gene 104 
expression and BP traits. We considered SNPs that reached genome-wide significance in the 105 
meta-analysis of common SNPs for each BP trait, and report 143 eQTL SNPs in 39 genes that 106 
had posterior probabilities of 80% or greater in either SBP, DBP or PP (Supplementary Tables 107 
5a-c and 7). There was a high degree of consistency between results from COLOC and S-108 
PrediXcan as 26 of 39 unique genes identified in the kidney were also observed across other 109 
tissues.  110 
Murine Kidney Single Cell Sequencing Analysis 111 
Homologs of human genes with greater than 80% posterior probability in colocalization analyses 112 
were further investigated for kidney cell type-specific RNA expression using single cell 113 
sequencing in murine kidney cells.  Cells were clustered into 11 groups representing structural 114 
features and other cell types found in the kidney. Eighteen of the 25 genes that showed 115 
enrichment of expression in any of the murine kidney cell clusters were enriched in five tubule-116 
related cell types: proximal tubules, loop of Henle, distal convoluted tubules, collecting duct 117 
peripheral cells and collecting duct intercalated cells (Figure 3; Supplementary Table 8a-c). 118 
Cross-referencing protein expression levels in the Human Protein Atlas29 confirmed findings 119 
from murine kidney, including higher expression of PNKD, SRR, SFXN2 and CLCN6 proteins in 120 
tubules compared to glomeruli (Supplementary Table 9). 121 
Assessment of Gene-Drug Relationships  122 
To better understand how genes identified in the study relate to medications that directly or 123 
indirectly affect BP, associations identified from the GPGE analyses were investigated for 124 
enrichment of gene targets for known antihypertensive medications, non-antihypertensive 125 
medications, and medications with adverse drug events (ADEs) for hypertension and 126 
hypotension (Supplementary Tables 10-12). We did not observe a significant difference between 127 
the proportion of genes targeted by any drug (22.6% and 20.5% annotated by nearest gene or 128 
GPGE association, respectively; χ2 P-value = 0.37), but found a significant difference in the 129 
proportion of genes targeted by antihypertensive drugs (5.2% and 21.7% for nearest gene or 130 
GPGE association, respectively; χ2 P-value = 6.7x10-16) (Supplementary Materials). We identify 131 
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175 gene-drug relationships between genes that increase BP with increasing GPGE and drugs 132 
that either inhibit or antagonize those genes (Supplementary Materials). The genes PDE3A, 133 
PSMB9, and SH2B3 targeted by the non-antihypertensive drugs theophylline, carfilzomib, and 134 
pazopanib, respectively, have adverse drug events of either hypo- or hypertension and increase 135 
BP with increasing GPGE (Supplementary Materials). These genes are potential targets for anti-136 
hypertensive drug development.  137 
Phenome-Wide Association Study (PheWAS) with BP Genetic Risk Scores 138 
To systematically evaluate pleiotropy between genetic predictors of BP-traits and diseases 139 
throughout the phenome, we performed PheWAS using BP-trait weighted genetic risk scores 140 
(GRS) in self-reported/administratively identified white individuals in the MVP.  We used all 141 
known and novel common index SNPs from the final meta-analysis to generate weighted genetic 142 
risk scores (w-GRS) for each BP trait and regressed PheWAS outcomes from MVP onto those 143 
scores, adjusted for the top 10 principal components. Eighty eight of 1,813 phenotypes were 144 
significantly associated with any of the three GRSs at a Bonferroni correct threshold of P < 145 
2.76x10-5 (Supplementary Table 13). Hypertension (smallest P < 1x10-305), essential 146 
hypertension (smallest P < 1x10-305) and hypertensive heart and/or renal disease (smallest P = 147 
3.3x10-173) were the top three associations for each of the three w-GRS. Associations with 148 
phenotypes in the circulatory system (N = 52) accounted for more than 50% of the significant 149 
results. The phenotype groups with the next most associations were endocrine/metabolic (N = 150 
28), genitourinary (N = 10) and hematopoietic (N = 6).  151 
Among significant associations, 45 were significant for all three w-GRS, 10 were 152 
significant for both SBP and DBP, and 15 were significant for both SBP and PP, demonstrating 153 
substantial overlap between signals captured by genetically predicted BP traits (Supplementary 154 
Figure 2; Supplementary Table 13). Thirteen associations were significant only for the PP w-155 
GRS, of which five were the diabetes sequelae ophthalmic manifestations, neurological 156 
manifestations, diabetic retinopathy, other abnormal glucose, and polyneuropathy. Four of the 157 
six hematopoietic associations were specific to anemias and were associated only with the PP w-158 
GRS. Aortic and other aneurysms were only associated with the DBP w-GRS, but not with other 159 
w-GRS.  160 
Convergence of Evidence 161 
Hypothesizing that convergence of evidence from multiple types of investigation 162 
(common and rare single variants, predicted gene expression, single-cell sequencing expression 163 
enrichment, and drug query) may inform functionally relevant gene targets, we scrutinized genes 164 
for which evidence of association was seen in three or more investigations (Table 3) and 165 
highlight a few novel genes. Paroxysmal nonkinesigenic dyskinesia (PNKD) expression was 166 
enriched in cells derived from the murine loop of Henle and distal collecting tubules. Signals for 167 
this novel locus were consistently associated with SBP across all analyses: GWAS, GPGE (in the 168 
adrenal gland) and colocalization (human kidney) (Table 3, Supplementary Tables 2a, 5a, and 169 
6a). RNA expression of leucine-rich repeat flightless-interacting protein 2 (LRRFIP2) was 170 
enriched in immune cells derived from murine kidneys, and was co-localized in human kidney. 171 
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Its predicted expression was inversely associated with PP in tissues derived from the aorta and 172 
tibial artery (Table 3, Supplementary Tables 5c, 6c, and 8c). We also detected SNPs associated 173 
with SBP in an intergenic region 131 kilobase (kb) downstream from the relaxin/insulin like 174 
family peptide receptor 2 gene (RXFP2; Table 3, Supplementary Table 2a). GPGE of RXFP2 in 175 
the adrenal gland, was positively associated with SBP and PP (Supplementary Tables 5a and 5c). 176 
The drugs Relaxin and Seralaxin target RXFP2 (Supplementary Table 11). We report 177 
associations between the novel intronic common SNP rs73080767 and PP, and a missense rare 178 
variant rs141325069 and SBP in the phosphodiesterase 3A (PDE3A) gene, as well as a positive 179 
association between GPGE and SBP in pancreas and subcutaneous adipose tissues (Table 3; 180 
Supplementary Tables 2c, 4c, and 5a). The PDE3A inhibitor theophylline used to treat chronic 181 
obstructive pulmonary disease has hypotension listed as a potential adverse drug event, which is 182 
consistent with the effects of increased gene expression in our analysis (Supplementary Tables 183 
11 and 12). Novel intronic SNPs in the adenosine kinase (ADK) gene were associated with SBP 184 
and its GPGE were positively associated with SBP and PP in the aorta among other tissues 185 
(Supplementary Tables 5a and 5c). 186 
 By focusing on genes identified from multiple analysis types, including single-cell RNA 187 
sequencing in murine kidney cells, we also report six previously-reported gene loci from the 188 
literature that are partially or fully re-annotated to new genes (Table 3). For example, our 189 
analysis identifies, the SRR gene instead of the SMG6 gene as a more plausible gene target for 190 
BP regulation. SRR gene expression was enriched in the proximal tubule of the mouse kidney, 191 
was identified by colocalization analyses in human kidney, and its expression was associated 192 
with SBP in a variety of tissues including atrial appendage, left ventricle, coronary artery, tibial 193 
artery, skeletal muscle, adrenal gland, and thyroid (Supplementary Tables 5a-c, 6a, 7, 8 and 9). 194 
Another previously-reported gene locus identified via the nearest gene annotation strategy of 195 
assigning relevant genes in the chromosome 10q24 region suggests Sideroflexin 2 (SFXN2) and 196 
SUFU negative regulator of hedgehog signaling (SUFU) as potential genes of interest11 (Table 197 
3). Although SUFU GPGE is associated with BP traits in various tissues, SFXN2 GPGE was 198 
associated with BP traits in the left ventricle as well as human kidney, and its expression is 199 
enriched in mouse kidney tubule cell types (Supplementary Tables 5a, 5c, 6c, and 8c). 200 
This study further characterizes the chromosome 1p36 region, which contains the 201 
methyltetrahydrofolate reductase (MTHFR) gene30, along with several genes important for blood 202 
pressure regulation including natriuretic peptide A (NPPA), natriuretic peptide B (NPPB) and 203 
chloride voltage-gated channel 6 (CLCN6). In addition to common GWAS-significant SNPs, we 204 
observed a novel rare missense variant (rs202102042; ArgGlu) in NPPA associated with PP 205 
(Table 2). NPPB GPGE was inversely associated with SBP and PP in the left ventricle, which is 206 
consistent with the known effects of this gene (Supplementary Tables 5a and 5c). CLCN6, a 207 
putative chloride antiporter31, was expressed in the tubule cell types of the mouse kidney, the 208 
SNP rs12741980 was identified by colocalization analysis as potentially causal for both SBP and 209 
CLCN6 expression in human kidney (Supplementary Table 6c). Among all known 210 
antihypertensive gene-targets, CLCN6 was most significant, with an inverse association between 211 
its GPGE and SBP in the tibial artery tissue (β = -2.76, P-value = 8.14x10-45; Supplementary 212 
Tables 5a and 10). 213 
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DISCUSSION  214 
Here we present the results from multi-omic analyses of a multi-stage transethnic GWAS 215 
consortium for BP traits. By incorporating large sample sizes, bioinformatics methods, and 216 
external measures of gene expression from a model system, we have re-interpreted the genetic 217 
architecture of BP, and identified tissues and anatomical features where BP genes are relevant. 218 
We report distinct relationships between each genetically predicted BP trait and features of the 219 
clinical phenome. Interrogation of gene-drug relationships and toxicities for GPGE associations 220 
provides additional evidence for known and novel BP genes and suggests target genes for drug 221 
development and repurposing of existing drugs as BP treatments. We emphasize the utility of 222 
large-scale GWAS of BP traits as a requisite starting point for downstream analyses that provide 223 
insights into clinical factors, genetic etiology, pathophysiology, and pharmacology of BP 224 
homeostasis. 225 
Convergent evidence from multiple analyses identified several novel BP genes including 226 
RFPX2, PDE3A and ADK. RXFP2 is a receptor for the pregnancy hormone relaxin32, which 227 
causes vasodilation, increases cardiac output and renal perfusion, and has been evaluated in 228 
clinical trials as a treatment for acute heart failure, although the results of the latest trial did not 229 
demonstrate a benefit33–35. RXFP2 is expressed in multiple tissues, which likely underlies the 230 
multiple physiological effects of the relaxin hormone throughout the circulatory system36.  231 
PDE3A is targeted by a wide variety of inhibitor drugs for which the indications vary and 232 
include congestive heart failure, hypertension, and heart disease. The PDE3A inhibitor 233 
theophylline used to treat chronic obstructive pulmonary disease has hypotension listed as a 234 
potential adverse drug event, which is consistent with the effects of increased gene expression in 235 
our analysis (Supplementary Tables 11 and 12). The autosomal dominant Mendelian condition 236 
Hypertension and Brachydactyly Syndrome (HTNB; OMIM: 112410) is caused by at least six 237 
distinct rare PDE3A mutations37,38. HTNB features include brachydactyly type E, severe salt-238 
independent but age-dependent hypertension, increased fibroblast growth rate, neurovascular 239 
contact at the rostral-ventrolateral medulla, altered baroreflex blood pressure regulation, and 240 
death from stroke before age 50 years when untreated39,40.   241 
The product of ADK, adenosine kinase, catalyzes the transfer of gamma-phosphate from 242 
ATP to adenosine to form adenosine monophosphate and has widespread effects on multiple 243 
systems including cardiovascular, nervous and respiratory systems41. Adenosine has negative 244 
inotropic, chronotropic, and dromotropic effects on the heart; it terminates supraventricular 245 
tachycardia (SVT) involving the AV node and has been attributed with cardiac brady-246 
arrhythmias42,43. Intravenous adenosine injection in humans induces vasodilation and systemic 247 
hypotension44, and is the primary drug used in the treatment of stable narrow-complex SVT45. It 248 
is known to reduce blood pressure and blood pressure variability in rats and its actions are known 249 
to be mediated through adenosine receptors46. ADK reduces adenosine availability, and 250 
increased expression would be biologically predicted to increase BP. This prediction is in 251 
agreement with our findings where we show a positive association between GPGE of ADK and 252 
SBP and PP in aortic tissue (Supplementary Tables 5a and 5c).  253 
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A novel aspect of this study is the incorporation of single-cell RNA sequencing 254 
expression data from cells derived from murine kidneys. We show that BP genes identified by 255 
eQTL colocalization analyses in human kidneys are enriched in tubule cell types derived from 256 
murine kidneys. Expression was enriched for BP genes in tubule cell types, suggesting a 257 
significant portion of BP regulation in the kidney may be orchestrated in tubules by genes 258 
detected through GPGE associations.   259 
Single-cell RNA sequencing in murine kidney identified genes for which expression was 260 
specifically enriched in immune cell types. For example, the protein encoded by LRRFIP2 binds 261 
to the cytoplasmic tail of toll-like receptor 4 to activate the nuclear factor kappa b signal 262 
pathway. It is also known to downregulate the NLR Family Pyrin Domain Containing 3 263 
(NLRP3) inflammosome by recruiting caspase-1 inhibitor flightless-1 to the inflammasome 264 
complex. Mice with spontaneous hypertension have increased levels of NLRP3 activation in the 265 
aorta and vascular smooth muscle cells47. Moreover, silencing of NLRP3 ameliorates 266 
hypertension through reduced activation of the inflammosomes47. NLRP3 deficiency has been 267 
shown to improve gestational hypertension in pregnant mice without affecting intrauterine 268 
growth restriction48. High expression of NLRP3 inflammosomes have been shown in aortas of 269 
patients with atherosclerosis49. These evidence combined with our study findings strongly 270 
suggest LRRFIP2 may reduce BP through downregulation of the NLRP3 pathway.  271 
We examined genes enriched in murine kidney cell types and identified six previously-272 
reported loci that were re-annotated by GPGE association (Table 3). Several lines of evidence 273 
implicate the SRR gene, while the nearest gene annotation strategy would identify the SMG6 as 274 
associated with BP at this locus. A SNP in SMG6, rs216172, has been associated with coronary 275 
artery disease50; however, the SNP is an eQTL for SRR and not for SMG6 (GTEx portal). SRR is 276 
an enzyme that catalyzes conversion of L-serine to D-serine, and eliminates water from L-serine 277 
to generate pyruvate and ammonia. The gene has also been associated with impaired cognitive 278 
function in mice51–53, supporting a growing body of evidence that connects the association 279 
between hypertension and age-related cognitive decline54,55.  280 
This work helps to clarify the complex MTFHR gene locus by providing unique tissue-281 
specific evidence for several genes in the region in relation to BP30. In addition to MTFHR, our 282 
study provides evidence for the role of NPPA (novel missense variant), NPPB (GPGE 283 
association with SBP and PP in the left ventricle), and CLCN6 (SNP colocalization in human 284 
kidney, and enrichment in murine kidney). NPPA and NPPB are exclusively expressed in the 285 
heart and have biological functions that include natriuresis, diuresis, vasorelaxation, inhibition of 286 
renin and aldosterone secretion, and a key role in cardiovascular homeostasis56. The evidence for 287 
CLCN6, a putative chloride antiporter31, was limited to analyses involving kidney tissues only. 288 
CLCN6 is targeted by the antihypertensive medication chlorthalidone, and NPPB is targeted by 289 
the antihypertensive medication carvedilol, while MTHFR is not targeted by antihypertensive 290 
medications (Supplementary Materials). Findings for this locus highlight how effects of multiple 291 
associated genes from the same locus may vary by tissue type, and several nearby genes with 292 
very different biological functions may jointly contribute to the trait of interest. 293 
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Several other genes with strong biologic plausibility and empirical evidence worth 294 
highlighting include cysteine conjugate beta lysine 2 (CCBL2), FES proto-oncogene, tyrosine 295 
kinase (FES), and acetylcholinesterase (ACHE) (Table 3). GPGE of CCBL2 in the tibial artery 296 
and adrenal gland was inversely associated with SBP (Supplementary Table 5a). The product of 297 
CCBL2, which encodes kynurenine aminotransferase 3 (KYAT3), is an aminotransferase that 298 
transaminates kynurenine to form kynurenic acid (KYA), a metabolite of tryptophan57. Direct 299 
administration of KYA in rats has been shown to reduce mean arterial pressure in spontaneously 300 
hypertensive rats, and microinjections of KYA block BP increases in glycine or glutamate 301 
injected rats58,59. Predicted expression of FES was inversely associated with SBP in the aorta, 302 
coronary artery and tibial artery tissues (Supplementary Table 5a). Naproxen, a non-steroidal 303 
anti-inflammatory drug, has an inhibitory effect on this gene (Supplementary Tables 11 and 12) 304 
and hypertension is one of its known side-effects60. ACHE terminates signal transduction at the 305 
neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft61. 306 
Notably, inhibition of acetylcholinesterase is an effective treatment for orthostatic hypotension, 307 
especially in patients with supine hypertension62. Dimetacrine, a tricyclic antidepressant, and 308 
decamethonium, a muscle relaxant, have inhibitory effects on ACHE and are not currently 309 
prescribed as anti-hypertension medications. 310 
To understand how genetically-predicted BP is associated with a diverse set of 311 
diagnoses, we calculated w-GRS weighted by estimates from each BP trait, and evaluated 312 
them with a PheWAS (Supplementary Table 13). The PP w-GRS was more likely to be 313 
associated with diabetic complications, including diabetic retinopathy and polyneuropathy, 314 
than w-GRS for SBP or DBP. PP is an independent predictor of cardiovascular disease and 315 
new-onset diabetes63,64. Elevated PP is a marker for arterial stiffness, which is positively 316 
associated with diabetic retinopathy and neuropathy65. Our finding of positive associations 317 
between the DBP w-GRS and aortic and other aneurysms support evidence from a previous 318 
study of 1.25 million individuals where a positive association between DBP and aortic 319 
aneurysms was reported66. Our study is the first to provide evidence for a genetic etiology for 320 
this reported association. 321 
 In conclusion, we applied multiple post-GWAS analyses and external resources to 322 
identify genes with effects on BP regulation. We report hundreds of novel SNPs and genes, 323 
previously-reported SNPs, and tissue-specific refinement of gene associations with meaningful 324 
directions of effects. We identified specific genes from gene-rich loci that are already targeted by 325 
antihypertensive drugs, and those already targeted by drugs with BP-related adverse events. Our 326 
study suggests that integrating tissue-specific expression into post-GWAS analysis provides 327 
greater insight into BP biology and potentially provides more actionable gene targets than the 328 
nearest gene approach.  329 
330 
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Figure 1. Study design schematic. Flowchart depicting strategy for the three association analysis strategies (common, rare, and exonic variants), 509 
as well as replication selection criteria and numbers of samples and SNPs by stage. Subsequent TWAS and PheWAS analyses using common 510 
variant summary statistics are also presented.  511 
 512 
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Figure 2. Manhattan plots summarizing GWAS results for (A) SBP, (B) DBP, and (C) PP. 513 
Manhattan plot of the discovery+replication meta-analysis. The y axis shows the –log10 P-values and the 514 
x axis shows the chromosomal positions. The horizontal red line represents the thresholds of P-value = 5 515 
x10-8 for genome-wide significance. SNPs in red are in at previously identified loci (discovery only) 516 
whereas SNPs in orange are at novel loci which were significantly replicated 517 
 518 
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Figure 3. Mapping BP-associated genes to kidney cell type clusters. Average expression level of GWAS/eQTL defined genes. Mean expression 519 
values of the genes were calculated in each cluster. Color scheme is based on z-score distribution. Each row represents one gene and each column 520 
is single cell type cluster (as defined by Park et al.) on the heatmap. Endo: endothelial, vascular, descending loop of Henle, Podo: podocyte, PT: 521 
proximal tubule, LOH: ascending loop of Henle, DCT: distal convoluted tubule, CD-PC: collecting duct principal cell, CD-IC: CD intercalated 522 
cell, Fib: fibroblast, Macro: macrophage, Neutro: neutrophil, NK: natural killer cell. 523 
 524 
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Table 1. Summary of known and novel loci achieving statistical significance from analysis of common variants. 525 
  Known Loci  Novel Loci   
 
     All novel P-value** 
 
Tier 1 
 
Tier 2 
 
Tier 3 
 
N Loci 
Average  
Effect* (SD) 
 
N Loci 
Average  
Effect* (SD) 
  
 
N Loci 
Average  
Effect* (SD) 
 
N Loci 
Average  
Effect* (SD) 
 
N Loci 
Average  
Effect* (SD) 
SBP 212 0.317 (0.151) 
 
128 0.240 (0.117) 7.8x10-7 
 
30 0.290 (0.154) 
 
39 0.232 (0.124) 
 
59 0.219 (0.075) 
DBP 76 0.267 (0.146) 
 
4 0.135 (0.016) 0.038 
 
2 0.135 (0.022) 
 
0 0 
 
2 0.135 (0.002) 
PP 205 0.269 (0.155) 
 
126 0.176 (0.089) 8.3x10-10 
 
21 0.189 (0.081) 
 
47 0.180 (0.092) 
 
58 0.168 (0.088) 
Total 298 -   207 -     - -   - -   - - 
Known loci: known loci were only tested for significance in the discovery sample (N = 459,776). Novel loci: tested in discovery sample and ICBP 526 
(N-Discovery = 459,776; N-replication = 299,024; Total N = 758,800) *Mean beta = average and standard deviation of the absolute value of beta-527 
estimates for each trait; **Represents P-value from two-sample t-test comparing mean beta for known loci and all novel loci. Tier 1 = First tier 528 
significance criteria: GWAS significance at discovery + replication passing Bonferroni threshold + consistent directions of associations between 529 
discovery and replication sets + GWAS significant at final meta-analysis; Tier 2 = Second tier significance criteria: GWAS significance at 530 
discovery + replication p-value < 0.05 + consistent directions of associations between discovery and replication sets + GWAS significant at final 531 
meta-analysis; Tier 3 = Third tier significance criteria: Suggestive significance at discovery + replication p-value < 0.05 + consistent directions of 532 
associations between discovery and replication sets + GWAS significant at final meta-analysis. 533 
534 
BP-PolyWAS: Main 24 
 
Table 2. Associations between missense variants identified in collaboration with consortia evaluating exonic variants and rare-variants.   535 
 536 
SNP Chr:BP Gene 
Amino 
Acid 
Change 
EA/ 
RA 
EAF 
SBP DBP   PP 
Effect P-value Neff Effect P-value Neff Effect P-value Neff 
rs141325069 12:20769270 PDE3A R-->Q A/G 0.0030 1.415 8.7x10-9 700771 0.716 2.7 x10-5 700575 0.759 5.2x10-5 700391 
rs139491786# 16:2086421 SLC9A3R2 R-->W T/C 0.0068 -1.917 4.6x10-21 651069 -1.323 1.9x10-22 651707 -0.643 1.9x10-5 649540 
rs61760904* 19:50139932 RRAS D->-N T/C 0.0073 1.160 1.1x10-12 844155 0.523 8.8x10-7 843327 0.668 2.0x10-8 843773 
rs73181210 3:169831268 PHC3 K-->E T/C 0.0107 0.855 3.7x10-8 845000 0.606 1.8x10-9 844834 0.230 4.2x10-2 842255 
rs3025380* 9:136501756 DBH G-->A C/G 0.0046 -1.137 1.9x10-8 864699 -0.825 7.2x10-10 863755 -0.321 3.0x10-2 864042 
rs139341533# 11:89182666 NOX4 L-->F A/C 0.0037 -0.814 2.1x10-4 851884 0.223 1.2x10-1 850481 -0.928 8.7x10-9 852260 
rs115079907 6:55924005 COL21A1 C-->R T/C 0.0023 1.259 2.1x10-3 837965 -0.582 3.2x10-2 831917 1.703 1.4x10-8 830745 
rs200999181*# 6:55935568 COL21A1 G-->V A/C 0.0014 1.900 9.2x10-6 724111 -1.038 4.3x10-4 718225 2.964 3.3x10-21 724615 
rs2764043*# 6:56035643 COL21A1 L-->P A/G 0.0016 -1.532 1.9x10-5 812384 0.353 1.4x10-1 814667 -1.925 2.4x10-13 810623 
rs138582164 8:95264265 GEM R-->. A/G 0.0011 3.247 2.1x10-7 633292 0.125 7.6x10-1 632884 3.159 6.0x10-12 632845 
rs202102042^ 1:11907171 NPPA R-->Q T/C 0.0004 3.863 3.1x10-7 765853 1.058 3.1x10-2 765853 3.198 2.4x10-8 765853 
*SNPs have been previously reported in the literature. #SNPs were identified in two different replication strategies: exonic set and rare-variant set. 537 
^ SNPs were replicated in the rare variants replication set. For SNPs that were available in both rare-variant and exonic analyses, table reports 538 
results with the largest sample size.  539 
540 
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Table 3. Converging evidence across analyses. 541 
Gene Novel 
Index SNPs 
(Common; Rare) 
Nearest  
Gene 
CVD Tissues  
(S-PrediXcan) 
Human 
Kidney 
(COLOC) 
Top eQTL 
Mouse 
Kidney 
Single Cell 
Clusters 
Related Drugs 
OAF Yes rs896693 OAF ↑;-;-;-;-;- rs508205 Tubules - 
PNKD Yes rs1870123 PNKD -;-;-;-;-;↓ rs3731861 Tubules - 
SNX32 Yes NA NA -;-;-;-;-;- rs694994 Tubules - 
CTSW Yes NA NA -;-;-;-;↓;- rs694994 Immune - 
CENPP Yes rs2761679 CENPP -;-;-;-;-;- rs10120915 Tubules - 
MXRA7 Yes rs7219390  MXRA7 -;-;-;-;-;- rs2286590 Glomerulus - 
UQCC1 Yes rs6142381 UQCC1 ↓;-;-;-↓;- rs2425056 b Glomerulus - 
KLHL42c Yes rs571463591 RN7SKP15 -;-;-;-;↓;- rs10842999 b Tubules - 
LRRFIP2c Yes rs7632108 GOLGA4 -;-;↓;-;↓;- rs7632108 Immune - 
HIST1H2BK Yes NA NA -;-;-;-;-;- rs1102565 Tubules - 
GTPBP10 Yes rs10270950 STEAP -;-;-;-;-;- rs10953006 Tubules - 
SRRc No rs12952051 SMG6 ↑;↑;-;↑;↑;↑ rs1048483 Tubules pyridoxal phosphate 
CEP68 No rs111524356 CEP68 ↑;↑;-;-;↑;- rs1009358b Tubules - 
CLCN6e No rs6669371; rs202102042 CLCN6 NPPA -;-;-;-;↓;- rs12741980 Tubules chlorthalidone; vincristine 
CDC16 No rs11617448 CDC16 ↑;↑;↑;↑;↑;↑ rs61972052 b Tubules - 
CDC25Ac No rs35979968 MAP4 ↓;↓;↓;↓;↓;- rs71323396 b Tubules - 
SLC35E2c No rs1014988 NADK -;-;-;-;-;- rs7546498 Tubules - 
PKN2cd No rs6679817 GTF2B -;-;-;-;-;- rs4142614 Tubules - 
CCBL2cd No rs6679817 GTF2B -;-;-;-;↓;↓ rs10922478 b Tubules - 
FES No rs2071382 FES -;-;↓;↓;↓;- rs2521498 b Immune naproxen 
NMT1 No rs12951622 NMT1 -;-;↑;↑;↑;- rs7405669 b Immune - 
SLC4A7 No rs2643826 SLC4A7 -;-;↓;-;-;- rs9845896 b Immune - 
SFXN2c No rs17114641 SUFU -;↑-;-;-;- rs11191356 Tubules - 
FADS1c No rs7125196 MIR4488 -;-;-;-;-;- rs174530 Tubules icosapent 
RXFP2 Yes rs9603376 RXFP2 -;-;-;-;-;↑ NA NA relaxin; serelaxin 
NPPBe No rs202102042 NPPA -;↓;-;-;-;- NA NA carvedilol 
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NPR3 No rs12656497 NPR3 -;-;-;-;-;↑ NA NA nesiritide 
PDE3A Yes rs73080767; rs141325069 VALUE MISSING -;-;-;-;-;- NA NA theophylline 
COL21A1 a No rs12203179; rs2764043 COL21A1 -;-;-;-;↑;- rs61524954 NA - 
ACHE ac No rs138475089 GNB2 -;-;↑;↑;↑;↑ NA NA dimetacrine; decamethonium 
ULK4 a No rs6797165  ULK4 -;↑;↑;↑;↑;↑ rs55835726 NA - 
Gene = Gene showed enriched expression in one or more cell type in murine kidney single-cell RNA sequencing experiment, or was significant in 542 
genetically predicted gene expression analysis for any of the 45 tissues; Novel = Indicator variable denotes whether variants in a given gene region 543 
have previously been reported in genome-wide association studies of BP traits. Index SNPs = Index SNP from common or rare variant analyses 544 
from each independent locus. Nearest Gene = Column reports genes that would have been identified if the nearest gene annotation strategy was 545 
used to link GWAS significant variants.  CVD Tissues = Column identifies genes that were significantly associated with genetically predicted 546 
gene expression and BP traits (using S-PrediXcan) in the following cardiovascular related tissues: atrial appendage, left ventricle, aorta, coronary 547 
artery, tibial artery and adrenal gland. Up (down) arrow indicates a positive (negative) association between GPGE and at least one BP trait. Dash 548 
indicates data was not significant or unavailable. For a full-set of tissue specific results, see Supplementary Tables 5a-5c. Mouse kidney single-549 
cell clusters = Column highlights the cell-type in which specific genes were enriched in murine single-cell RNA sequencing expression analyses. 550 
Related Drugs = Column summarizes drug targets which were identified to interrelate with the gene from xyz databases.  551 
a Genetically predicted expression of these genes were positively associated with SBP and PP, but inversely associated with DBP; for all other 552 
genes directions of associations were consistent across traits.  553 
b Gene had several significant eQTLs; presented SNP represents the most significant eQTL. 554 
c Mismatch between post-GWAS expression based gene identification and nearest gene annotation strategy 555 
d,e Genes are in the same locus 556 
 557 
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ONLINE METHODS 558 
We conducted a multi-stage GWAS of common and rare variants in over 700,000 participants. 559 
We then performed additional bioinformatics analyses of GPGE for BP traits, evaluated cell 560 
types where associated genes are expressed, performed a phenome-wide association study of 561 
genetic risk scores for BP traits from the electronic health records of MVP participants, and 562 
screened known drugs to evaluate potential for repurposing and validate observed associations. 563 
A flow chart for analyses is presented in Figure 1.  564 
Discovery Cohorts 565 
The Million Veteran Program 566 
The Million Veteran Program (MVP) is a large cohort of fully-consented participants who were 567 
recruited from the patient populations of 63 Department of Veterans Affairs (VA) medical 568 
facilities. Recruitment began in 2011 and is conducted in-person, which is initiated by an 569 
invitation letter and completed by answering baseline and lifestyle questionnaires, providing a 570 
blood sample, providing access to medical records, and giving permission for re-contact. 571 
Consent to participate is provided after counseling by research staff and mailing of informational 572 
materials. All documents and protocols have been approved by the VA Central Institutional 573 
Review Board. Blood samples are collected by phlebotomists and banked at the VA Central 574 
Biorepository in Boston, MA. Genotyping was conducted using a customized Affymetrix Axiom 575 
Biobank Array chip with additional content added to provide coverage of African and Hispanic 576 
haplotypes, as well as markers for common diseases in the VA population. Researchers are 577 
provided with de-identified versions of these data, and do not have the ability or authorization to 578 
link these details with a participants’ identity. 579 
MVP Genotype QC 580 
Blood samples drawn from consenting MVP participants were shipped to the VA Central 581 
Biorepository in Boston, MA, where DNA was extracted and shipped to two external genotyping 582 
centers for genotyping on an Affymetrix Axiom Biobank array designed specifically for the 583 
MVP. The MVP genomics working group applied standard quality control and genotype calling 584 
algorithms to the data in batches using the Affymetrix Power Tools Suite (v1.18). Standard 585 
quality control pipelines were used to exclude duplicate samples, samples with more 586 
heterozygosity than expected, samples with an excess (>2.5%) of missing genotype calls, and 587 
samples with discordance of genetically inferred sex versus self-report. Related individuals 588 
(halfway between 2nd and 3rd degree relatives or closer) as measured by the KING software67 589 
were also excluded. Prior to imputation, variants that were poorly called or that deviated from 590 
their expected allele frequency based on reference data from the 1000 Genomes Project68 were 591 
excluded. After pre-phasing using EAGLE v269, genotypes from the 1000 Genomes Project68 592 
phase 3, version 5 reference panel were imputed into Million Veteran Program (MVP) 593 
participants via Minimac3 software70. Principal component analysis was performed using the 594 
FlashPCA71, to generate the top 10 genetic principal components explaining the greatest 595 
variability. 596 
Race/Ethnicity 597 
Information on race (whites, blacks, Asians, and Native Americans) and ethnicity (Hispanic: Yes 598 
or No) were obtained based on self-report through centralized VA data collection methods using 599 
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standardized survey forms, or through the use of information from corporate data warehouse 600 
(CDW), or Observational Medical outcomes Partnership (OMOP) data, when information from 601 
self-report survey was missing. Race and ethnicity categories were then merged to form the 602 
following administratively assigned race/ethnicity variables: non-Hispanic whites (whites), non-603 
Hispanic blacks (blacks), non-Hispanic Asians (Asians), non-Hispanic Native Americans (Native 604 
Americans) and Hispanics. Individuals for whom race and ethnicity could not be confidently 605 
assigned due to conflicting records and missing data, were categorized as unknown. Prior to 606 
analysis QC, there were 15,710 Veterans with unknown status for race/ethnicity. For these 607 
individuals, we used a K-means clustering approach in R following the McQueen algorithm with 608 
the top 10 genetic principal components as input variables. In order to obtain the most reliable 609 
cluster designations for the missing data, the k-means approach was applied to the maximum 610 
available samples: the 1000 Genomes reference populations and all individuals for whom PCs 611 
were available regardless of whether race/ethnicity designations were unknown. K-clusters were 612 
optimized by testing values K=2 through K=10. K = 4 was ultimately chosen as the most optimal 613 
value, as visual examination of these most closely corresponded to whites (N=5,265), blacks 614 
(N=4,671), Asians (N= 3,936) and Hispanics (N= 1,838). 615 
MVP BP Phenotypes 616 
We selected adults (age ≥ 18) and used the earliest median eligible non-Emergency Department 617 
outpatient measured SBP in the EHR, and also used the corresponding DBP from this measure. 618 
Measures are ineligible if they occur at or after an ICD-9 code from the groups 585, 405, or 428. 619 
If pain scores were available, we censored BP measures taken during encounters when a pain 620 
score ≥ 5 was recorded, because severe pain can elevate BP72,73. For measures taken while a 621 
patient was on an antihypertensive medication we added 15 mmHg to SBP and 10 mmHg to 622 
DBP8,74. 623 
MVP Analysis 624 
For the MVP GWAS we performed linear regression association tests with additive models for 625 
untransformed BP traits, after adjusting for medication use. We adjusted linear regression models 626 
analyzing SNP associations for age at BP measure, age2, sex, BMI measured within 1 year of BP 627 
measure, and the top 10 genetic principal components in analyses. All primary analyses for the 628 
MVP were conducted by either strata of administratively assigned race/ethnicity or by their 629 
empirically designated clusters. All regression based analyses were conducted in SNPTEST-630 
v2.5.4-beta75. Inference was limited to genotyped and imputed variants with SNPTEST Info 631 
scores of 0.4 or higher, with Hardy Weinberg equilibrium p-value > 5x10-8 for common variant 632 
analysis (minor allele frequency > 0.1). Inference rare variants, SNPs with MAF ≤ 1%, was 633 
further restricted to variants with an estimated minor allele count (SNPTEST Info score 634 
multiplied by minor allele count) of 10 or higher in each analysis sub-cohort.  635 
The UK Biobank 636 
Summary statistics from the analysis of the interim data from the UK Biobank (UKB) were 637 
utilized in our meta-analysis. These results have been previously reported by Warren et al12. 638 
Briefly, following central and study-specific quality control protocols, 140,886 empirically 639 
classified white individuals were analyzed for SBP, DBP, and PP traits. BP measures were 640 
averaged over two measures, and adjusted for medication use by adding 15 and 10 mmHg to 641 
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SBP and DBP, respectively. Linear models were adjusted for the top 10 principal components of 642 
ancestry, age, age2, sex, an indicator for genotyping platform, and BMI.   643 
Meta-Analysis of Discovery Datasets 644 
Inverse-variance weighted fixed-effects meta-analysis of common variants across MVP subsets 645 
and summary statistics from UKB was performed using the METAL software. Genomic inflation 646 
factor was calculated, and λGC for the discovery from MVP were 1.195, 1.149, and 1.171 for 647 
SBP, DBP and PP, respectively, 1.303, 1.315, and 1.270 respectively, from UKB, and 1.275, 648 
1.140, and 1.244, respectively, in the overall discovery analysis (Supplementary Fig. 3).  649 
Selection of SNPs for Replication 650 
Common Variants 651 
For common variants, we considered for follow-up SNPs in loci non-overlapping with 652 
previously reported loci according to both an LD threshold of r2 ≤ 0.1 and a 1Mb interval. We 653 
obtained a list of these SNPs with p-value < 1x10-6 for any of the three BP traits, a minor allele 654 
frequency (MAF) ≥ 1%, and concordant directions of effect between UKB and MVP. 655 
In silico replication summary statistics were provided for 942 SNPs by the International 656 
Consortium for Blood Pressure Genetics (ICBP) after meta-analysis of 77 individual 657 
participating cohorts for a total maximum of 299K individuals, who were genotyped and 658 
analyzed according to study-specific protocols. Additional replication results were provided from 659 
Vanderbilt University’s BioVU EMR-linked biorepository, among which genotypes from the 660 
MEGA array and phenotype data were available from 17,277 participants. Discovery and 661 
replication data were combined using fixed-effects inverse-variance weighted meta-analysis 662 
implemented in METAL76. 663 
Rare Variants 664 
We conducted an in silico replication analysis of 18 rare exonic SNPs from our discovery 665 
analysis in 417,143 participants from the BP-ICE consortium. SNPs were chosen for replication 666 
if they had a discovery p-value < 1x10-6, and a MAF < 1%.  667 
Due to BP-ICE’s emphasis on exonic rather than rare variation, we also pursued additional 668 
replication utilizing the larger release of the UKB data in order to capture non-exonic rare 669 
variation. Due to the inclusion of UKB data in the discovery set, for the second analysis we 670 
sought replication from variants suggestive only in MVP cohorts following meta-analysis as 671 
described above. 1,066 rare variants with p-value < 1x10-6 for any of the three phenotypes were 672 
selected for replication in 458,577 participants from UKB.  Additional replication was provided 673 
as above from the BioVU MEGA genotyping, and all data was meta-analyzed using fixed-effects 674 
meta-analysis in METAL76. 675 
Classifying Results by Evidence for Association 676 
For results that reach statistical significance of p-value ≤ 5x10-8 at any stage of the analysis, and 677 
that had consistent direction of effect between discovery and replication stages, we established 678 
three tiers of evidence that are annotated in results tables: 679 
1) Genome-wide significance in the discovery stage, and Bonferroni-corrected significance 680 
in replication. 681 
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2) Genome-wide significance in the discovery stage, and p-value ≤ 0.05 in the replication 682 
stage. 683 
3) All other associations reaching genome-wide significance across stages regardless of 684 
discovery or replication p-values.  685 
Genetic Risk Score Construction 686 
We constructed a genetic risk score (GRS) for each BP trait by calculating a linear combination 687 
of weights derived from the 140,886 participants from the UKB common variant analysis and 688 
index SNPs at each statistically significant locus observed in the MVP. Weighted GRS (w-GRS) 689 
were constructed for self-reported/administratively assigned white individuals in the MVP only.   690 
Phenome-Wide Association Study Analysis 691 
We performed a phenome-wide association study (PheWAS)77,78 of GRS for each BP trait in 692 
MVP whites, leveraging the full catalog of ICD-9 diagnosis codes. We used logistic regression to 693 
separately model each of 1,813 PheWAS traits as a function of the three GRSs, adjusted for age, 694 
age2, sex, BMI, and 10 PCs. We report the results from these analyses as odds ratios where the 695 
estimate is the average change in odds of the PheWAS trait per weighted BP-increasing allele. 696 
Multiple testing thresholds for significance were set to p-value ≤ 2.75x10-5(0.05/1,813). All 697 
PheWAS analyses were conducted using the R PheWAS package79.  698 
S-PrediXcan Analysis 699 
Genetically predicted gene expression was evaluated for the common variant subset with S-700 
PrediXcan80, a gene-level approach which estimates the genetically determined component of 701 
gene expression in a given tissue and tests it for association with SNP-level summary statistics. 702 
We utilized all three BP meta-analysis results for common variants and 44 tissues from GTEx25 703 
for this analysis, incorporating covariance matrices developed for European populations (1000 704 
Genomes) as the majority of samples were European in origin.  705 
For evaluating the accuracy of gene annotations for BP and HTN loci available in the 706 
GWAS catalog, significant S-PrediXcan results were considered if the expressed gene was 707 
within 1MB of the nearest gene to the top SNP (within 250kb, annotated using SNPDOC 708 
https://wakegen.phs.wakehealth.edu/public/snpdoc3/index.cfm). Previously identified loci 709 
annotations were considered “consistent” if the only significant expressed gene (in any tissue) 710 
matched the nearest gene, “partially consistent” if a significant expressed gene (in any tissue) 711 
matched the nearest gene and other expressed genes were also significant, and “inconsistent” if 712 
none of the significant expressed genes matched the nearest gene for the known locus.  713 
Evaluation of Associated Loci as Kidney eQTLs 714 
The GTEx resource lacks sufficient kidney tissue specimens to build predictive models for S-715 
PrediXcan analysis, so we used the collection of kidney reference data that was recently 716 
described by Ko et al28. We considered all tiers of statistically significant SNPs in this analysis, 717 
and used COLOC27 to calculate the posterior probability that the locus is both causal for the BP 718 
trait and causal for observed expression changes at a nearby gene. We present all SNP-gene pairs 719 
with a posterior probability of 0.95 or greater. For the genes implicated by the COLOC analysis, 720 
we also evaluated homologous genes in the single cell atlas of the mouse kidney, where 721 
expression levels are measured by single-cell RNAseq across 57,979 total mouse kidney cells 722 
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from 7 healthy mice81. This enables us to observe what cell types in the mammalian kidney 723 
express the genes where there is evidence for association between expression and BP traits. A 724 
single cell-gene matrix containing the UMI (unique molecular identifier) counts for 43,745 cells 725 
and 16,273 transcripts were generated from 7 normal mouse kidneys using 10x ChromiumTM 726 
Single cell solution81. Original raw data files were deposited under GEO (GSE107585). The 727 
target genes of GWAS signals were identified by integrative statistical analysis of kidney eQTL 728 
result from 99 normal human kidney cortex samples28 and GWAS signals using Bayesian 729 
colocalization approach coloc. Mouse orthologs for the human genes were found using Ensembl 730 
BioMart (http://www.ensembl.org/biomart/martview). Genes expressed less than 5% of the cell 731 
clusters were excluded from further analysis. To calculate the average expression level for each 732 
cluster, a z-score of UMI count was first obtained for every single cell. Then, we calculated the 733 
mean z-scores for individual cells in the same cluster, resulting in z-score for each gene and each 734 
cell cluster.  735 
Evaluation of Drug Classes for Genes with Associations with Gene Expression 736 
For genes with associations between GPGE and BP traits, we evaluated existing drugs for target 737 
gene and adverse drug events (ADEs), as well as cataloging whether the targets of known anti-738 
hypertension drugs are detected, and identifying genes with potential for inhibitive drug targeting 739 
where increasing GPGE also increases BP and are currently targeted by a non-antihypertensive 740 
drug.  741 
A list of medications with a primary indication for hypertension and a list of medications 742 
with adverse drug events (ADEs) for hypertension and hypotension indications were created 743 
using SIDER82 and the DEB2 database83. Gene targets for antihypertension medications 744 
(Supplementary Table 14), medications targeting genes significant in S-PrediXcan analyses with 745 
positive effect sizes (Supplementary Table 15), and medications targeting genes mapped from 746 
significant GWAS signals (Supplementary Table 16) were queried using DGIdb84 747 
(http://www.dgidb.org/). Primary indications for medications targeting genes significant in S-748 
PrediXcan analyses with positive effect sizes were compiled using the BIDD TTD database85 749 
(Supplementary Table 11; https://db.idrblab.org/ttd/). Genes targeted by antihypertension 750 
medications with a significant S-PrediXcan association in at least one tissue with at least one BP 751 
trait are presented in Supplementary Table 10 alongside the most significant S-PrediXcan result. 752 
S-PrediXcan genes associated with any trait, that have positive effect sizes in any tissue, and are 753 
targeted by a non-hypertension drug are presented in Supplementary Table 11 with the name of 754 
the drug and the primary indication for treatment. S-PrediXcan genes associated with any trait, 755 
targeted by a drug, and that have an ADE involving hypertension or hypotension are presented in 756 
Supplementary Table 12. Sample proportions presented in results and Supplementary Data were 757 
compared using a two-proportion z-test.  758 
 759 
 760 
 761 
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